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Abstract
Background: Neurodevelopmental disorders (NDDs) such as autism spectrum disorder, intellectual disability,
developmental disability, and epilepsy are characterized by abnormal brain development that may affect cognition,
learning, behavior, and motor skills. High co-occurrence (comorbidity) of NDDs indicates a shared, underlying
biological mechanism. The genetic heterogeneity and overlap observed in NDDs make it difficult to identify the
genetic causes of specific clinical symptoms, such as seizures.
Methods: We present a computational method, MAGI-S, to discover modules or groups of highly connected
genes that together potentially perform a similar biological function. MAGI-S integrates protein-protein interaction
and co-expression networks to form modules centered around the selection of a single “seed” gene, yielding
modules consisting of genes that are highly co-expressed with the seed gene. We aim to dissect the epilepsy
phenotype from a general NDD phenotype by providing MAGI-S with high confidence NDD seed genes with
varying degrees of association with epilepsy, and we assess the enrichment of de novo mutation, NDD-associated
genes, and relevant biological function of constructed modules.
Results: The newly identified modules account for the increased rate of de novo non-synonymous mutations in
autism, intellectual disability, developmental disability, and epilepsy, and enrichment of copy number variations
(CNVs) in developmental disability. We also observed that modules seeded with genes strongly associated with
epilepsy tend to have a higher association with epilepsy phenotypes than modules seeded at other
neurodevelopmental disorder genes. Modules seeded with genes strongly associated with epilepsy (e.g., SCN1A,
GABRA1, and KCNB1) are significantly associated with synaptic transmission, long-term potentiation, and calcium
signaling pathways. On the other hand, modules found with seed genes that are not associated or weakly
associated with epilepsy are mostly involved with RNA regulation and chromatin remodeling.
Conclusions: In summary, our method identifies modules enriched with de novo non-synonymous mutations and
can capture specific networks that underlie the epilepsy phenotype and display distinct enrichment in relevant
biological processes. MAGI-S is available at https://github.com/jchow32/magi-s.
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Background
Phenotypic heterogeneity in neurodevelopmental disor-
ders (NDDs) has been well documented and includes
variability in the severity of symptoms, age of onset, and
comorbidity of distinct clinical phenotypes in affected
individuals [1]. For example, more than 30% of individ-
uals with autism spectrum disorders are estimated to
have epilepsy [2], and individuals with epilepsy have an
increased comorbidity of autism and intellectual disability/
developmental disability (ID/DD) compared with individ-
uals without epilepsy [3, 4]. The comorbidity of nosologi-
cally distinct phenotypes is reflected in an overlap of
causative genes and the involvement of similar molecular
processes for these disorders [5, 6]. For example, SCN2A,
the causative gene for epilepsy-associated Dravet syn-
drome, is also a primary candidate gene for familial autism
[7, 8], while NRXN1 has been associated with epilepsy as
well as autism, schizophrenia, and developmental disability
[9, 10]. In fact, nearly all genes with identified de novo mu-
tations in epilepsy cases [11, 12] also have identified de
novo mutations for other NDDs [13, 14].
While indicative of the shared biological pathways of
NDDs, the high degree of pleiotropy for candidate NDD
genes has made the classification of candidate genes and
the discovery of novel genes towards distinct develop-
mental features difficult. To date, several computational
approaches have been devised to identify shared path-
ways of candidate genes for genetic disorders [15–23].
These approaches generally combine mutations identi-
fied from sequencing data of affected individuals with
gene interaction networks and/or co-expression data to
group genes with mutations in the same pathway. For
example, we previously described MAGI, a tool to iden-
tify modules of genes significantly enriched for de novo
variants in individuals with autism and ID/DD by inte-
grating both protein-protein interaction networks and
RNA sequencing data with variant calls [16]. Using this
method, we identified distinct gene modules for signal-
ing pathways and synaptic transmission from a set of de
novo variants, and patients with mutations in these
modules were observed to have more severe ID pheno-
types than other patients. However, these methods do
not allow for isolation of gene modules and pathways that
are associated with a specific phenotype, such as epilepsy,
compared with those that are more generally associated
with multiple NDDs. Network and expression-based inte-
gration approaches that can accomplish this task are neces-
sary to further understand the phenotypic heterogeneity of
NDD-associated genes [1, 24].
Here, we present MAGI-S, an extension of our
method MAGI, that identifies modules consisting of
genes with high connectivity in the co-expression and
protein-protein interaction networks that are also highly
co-expressed with an input “seed gene.” We have used
MAGI-S to predict potential NDD modules that might
help in dissecting the wide phenotypic and genotypic
heterogeneity of NDDs. Our approach is based on the
assumption that variants in genes that are highly inter-
acting in protein-protein interactions networks and
are highly co-expressed during brain development have
a higher chance of manifesting similar phenotypes than
variants in genes with a low degree of interaction. Using
diverse sets of known candidate NDD genes, we utilized
MAGI-S to identify modules of genes that are associated
with NDD and can dissect the epilepsy phenotypes in
NDD. We found that (i) most modules are significantly
enriched for de novo mutations in affected probands
with NDDs versus unaffected siblings, (ii) the union of
genes in all modules related to epilepsy contains novel
gene candidates for epilepsy, and (iii) these modules can
dissect the epilepsy phenotypes for some NDD cases. Based
on this analysis, we provide evidence that studying modules
of related genes can be useful for better understanding the
biomolecular causes of epilepsy phenotypes in NDDs.
Methods
MAGI-S
We previously developed MAGI [16], a tool for predict-
ing pathways and modules significantly enriched for de
novo variants associated with NDDs in cases compared
to controls [16]. MAGI is a randomized algorithm that
constructs genetic modules containing a set of related
genes that are highly co-expressed during brain develop-
ment, highly connected in protein-protein interaction
networks, have very few severe variants in control popu-
lations, and are significantly enriched among de novo
variants in affected individuals. Specifically, MAGI first
assigns a score si to each gene i based on the number of
de novo variants present in the affected cases, while ac-
counting for gene length and distribution of de novo
non-synonymous mutation [16]. Next, MAGI finds a set
of genes, M, that maximizes a standardized score of the
selected genes ( i:e:; SM ¼
P
i∈M
siffiffiffiffiffi
jMj
p ) while satisfying the
connectivity conditions for both protein interaction and
co-expression networks.
Here, we developed MAGI-S, a method which differs
from MAGI in that MAGI-S uses a known disease gene as
the input “seed gene” to identify a module that is highly
co-expressed with the seed gene, rather than using de
novo variants observed in affected cases, as in MAGI [16].
The objective of MAGI-S is to discover a set of genes (i.e.,
module) that share similar biological function with the
seed gene. MAGI-S utilizes the co-expression network
built using the BrainSpan Atlas of the Developing Human
Brain [25], high-quality protein interactions from the Hu-
man Protein Reference Database and STRING, and loss-
of-function (LOF) variants from a set of normal/control
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samples (see Additional file 1) (Fig. 1, Additional file 1:
Figure S1) [26, 27].
MAGI-S assigns a score to each gene based on the rela-
tive ranking of the co-expression of that gene and the input
seed gene. MAGI-S then finds a set of genes that are highly
connected across interaction networks, have a low number
of severe variants in control samples, and are highly co-
expressed with the input seed gene. The MAGI-S algo-
rithm, similar to MAGI, has two main steps. First, it finds a
set of connected paths with a length between 5 and 8 genes
in protein interaction networks that have a high summa-
tion of gene scores. Second, similar to MAGI, it utilizes a
random walk and local search approach to cluster the con-
structed paths found in the first step into modules while
satisfying the connectivity and co-expression constraints
(see Additional file 1). This procedure is repeated, and the
module with the highest score is selected.
Seed genes
MAGI-S allows any gene to be considered as the seed gene
and produces modules centered around that gene. In this
study, we consider over 100 well-known neurodevelopmen-
tal genes as input seed genes. We applied MAGI-S on a
comprehensive set of seed genes known to contribute to
NDDs found using different whole-exome and genome
sequencing studies. We have considered all the genes re-
ported in the SFARI gene list which were ranked as having
the most evidence for contribution to autism by their
analysis [28]. More formally, known NDD seed genes were
selected from the following main databases: (i) the genes
from SFARI Gene database with most evidence of contribu-
tion to NDD (i.e., gene scores of either 1 or 2 with a total of
84 genes), (ii) the genes that have been concurrently re-
ported to be associated with epilepsy in OMIM, DDG2P,
EpilepsyGene, and a recent review paper of epilepsy genes
(total of 41 genes, 4 of which also have SFARI gene scores
of either 1 or 2) [28–32], and (iii) an additional 6 genes
moderately associated with epilepsy (FLNA, FMR1, GRIN1,
HNRNPU, NECAP1, NEDD1L) (Additional file 1: Table S1).
We have mainly focused on epilepsy as the phenotype of
interest to investigate in patients with NDDs from discov-
ered modules. In summary, we have considered a total of
127 genes which are known to be significantly associated
with NDD phenotypes as input seed genes to MAGI-S. Due
to a required minimum average co-expression, 16 potential
seed genes failed to produce a module, yielding a total of
111 distinct modules. Note that many of these genes were
selected based on the results available through whole-exome
sequencing (WES) or whole-genome sequencing (WGS) of
NDD cases/probands.
Fig. 1 General overview of MAGI-S. A seed gene (e.g., SCN1A), protein-protein interaction (PPI) network, co-expression network, and LOF
mutations in control samples are provided to MAGI-S to produce a seed centric module. Each gene in the PPI and co-expression networks is
assigned a score based on the gene’s degree of co-expression with the seed gene relative to all other genes in the networks. Seed pathways
are high-scoring simple paths formed from genes that are highly co-expressed relative to the seed gene, connected in the PPI network, and
have a low number of LOF variants in control samples. Seed pathways are clustered into modules via a random walk of a graph created by
seed pathways, and the total score of a module is improved by local search (similar to the MAGI algorithm in Hormozdiari et al. [16]). MAGI-S
is run with varied parameters related to module size, minimum co-expression, and minimum PPI density, and the highest scoring module is
retrieved. We have used the human developmental data from BrainSpan Atlas for the co-expression network construction. Furthermore, the
combination of protein interactions from HPRD and STRING datasets was used as the PPI networks in our analysis
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We first assigned the seed genes into three groups ac-
cording to the known level of association with the epilepsy
phenotype based on available disease-phenotype databases
and literature [28, 30–34]. The three seed gene groups
(classes) were defined based on reported epilepsy annota-
tion from the following well-known sources: OMIM,
DDG2P, EpilepsyGene, and Wang et al. [30, 31, 34]. We
assigned the seed genes which were concurrently anno-
tated by all four of these resources to be associated with
epilepsy as class 1. Genes which were annotated to be as-
sociated in only a subset of the above resources were
assigned to class 2. Finally, seed genes which were not as-
sociated with epilepsy in any of the above resources were
assigned to class 3 (Additional file 1: Table S1).
These three different classes of seed genes represent
the degree of evidence in the literature for their associ-
ation with epilepsy phenotype. The specified grouping is
based on the decreasing degree of known association
with seizure of these seed genes as follows:
 Class 1 (ARHGEF9, ALDH7A1, ALG13, CACNA1H,
CACNB4, CDKL5, CHD2, CHRNB2, DEPDC5,
DNM1, EEF1A2, GABRA1, GABRB3, GABRG2,
GNAO1, GRIN2A, GRIN2B, HCN1, KCNB1,
KCNMA1, KCNQ2, KCNT1, KCTD7, LGI1,
PCDH19, PRRT2, SCN1A, SCN1B, SCN2A, SCN8A,
SLC25A22, SPTAN1, STX1B, STXBP1, TBC1D24)
 Class 2 (ASH1L, BCKDK, CACNA1D, CNTNAP2,
DIP2C, DYRK1A, FLNA, FMR1, GRIN1, HNRNPU,
KMT2A, MBOAT7, MECP2, NECAP1, NEDD4L,
PTEN, RANBP17, SCN9A, SLC6A1, SYNGAP1, TRIO)
 Class 3 (ADNP, ANK2, ANKRD11, ARID1B, ASXL3,
BAZ2B, BCL11A, CHD8, CIC, CTNND2, CUL3,
DDX3X, DSCAM, ERBIN, GIGYF2, GRIA1, GRIP1,
ILF2, INTS6, IRF2BPL, KDM5B, KDM6A, KMT2C,
KMT5B, LEO1, MED13, MED13L, MET, MYT1L,
NAA15, NCKAP1, NLGN3, NRXN1, PHF3, POGZ,
RIMS1, SETD5, SHANK2, SHANK3, SMARCC2,
SPAST, SRCAP, SRSF11, TAOK2, TBL1XR1, TBR1,
TCF20, TNRC6B, TRIP12, UBN2, UPF3B, USP15,
USP7, WAC, WDFY3)
Class 1 seed genes include genes which have the most in-
dication of being involved with epilepsy-associated pheno-
types based on available databases and literature [28, 30–34].
On the other hand, class 3 are seed genes which have the
least/no amount of evidence to be involved with the epilepsy
phenotype based on the literature and are more associated
with other neurodevelopmental phenotypes.
Enrichment of de novo mutations and CNV from affected
cases in modules
To assess the enrichment of de novo mutation in NDD
cases relative to controls, de novo mutations were
retrieved from denovo-db (version 1.6) [27]. denovo-db is
a database of germline de novo variants that have been
identified by next-generation sequencing technology ag-
gregated from 54 different studies with rigorous pheno-
typing standards (Additional file 1). Variants within
denovo-db have been curated to include information such
as genomic position, reference and alternate alleles, func-
tional category, associated phenotypes of the individual
possessing the variant, and orthogonal validation status.
The largest set of de novo variants used in our analysis are
from the Simons Simplex Collection (SSC), which in-
cludes the de novo variation of both affected ASD pro-
bands and unaffected siblings. The other denovo-db
studies used in our analysis have also had the highest
quality of de novo call sets with a very low false discovery
rate and similar rates of de novo variation. The complete
set of missense (and missense-near-splice) or loss-of-
function (frameshift, splice donor, splice acceptor, stop-
gained, stop-gained-near-splice, stop-lost) mutations from
the denovo-db resource for Simons Simplex Collection set
[35–41], Autism Sequencing Consortium (ASC) [42],
MSSNG [43, 44], Deciphering Developmental Disorders
(DDD) [29], Epi4K [11], Helbig et al. [45], intellectual dis-
ability studies [46–49], and schizophrenia studies [50–54]
were considered. In total, we study 12,199 NDD patients
with ASD, ID, DD, or epilepsy and 1933 sibling/control
individuals (Additional file 2: Table S2: “denovo-db”).
To determine the enrichment of copy number dele-
tions and duplications within NDD cases relative to
controls, we retrieve a copy number variant (CNV) mor-
bidity map previously constructed from 29,085 children
with developmental delay and 19,584 controls [60]. We
assess the intersection of CNVs with genes within each
module (Additional file 1).
Dissection of epilepsy phenotype by enrichment of
epilepsy genes within modules
To evaluate the enrichment of de novo non-synonymous
variation specific to different cohorts of NDDs within each
module, we use Fisher’s exact test to measure the enrich-
ment of de novo variation in probands with either (1)
ASD, ID, or DD, or (2) epilepsy relative to controls. Add-
itionally, to quantify the enrichment of modules for genes
with phenotypic annotations associated with either (1)
NDDs without epilepsy or (2) NDDs with epilepsy, we
calculated an enrichment score for each module as (MP/
MP′)/(GP/(19, 986 −GP)), where MP is the number of
genes annotated as a certain NDD phenotype inside a
module and MP′ is the complement, and GP is the total
number of genes annotated as a certain phenotype. There
is a total of 19,986 protein-coding genes in the human
genome (Gencode GRCh38.p12). Phenotypic annotations
were retrieved from SFARI, OMIM, DDG2P, Epilepsy-
Gene, or Wang et al. (Additional file 1) [28, 30–32].
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Pathway and ontology enrichment and expression
analyses of modules
To describe pathway, gene ontology, and disease enrich-
ment within a module, we provided a list of the genes
within a module and its respective seed gene to Enrichr
(http://amp.pharm.mssm.edu/Enrichr/) to produce path-
way and GO biological process and Reactome pathway
enrichments and OMIM disease annotations [55, 56].
We provided the same gene lists and the union of gene
lists belonging to the same class to the cell type-specific
expression analysis (CSEA), specific expression analyses
(SEA), and tissue-specific expression analyses (TSEA)
tools to assess the selective expression profiles of mod-
ules in the human brain and body [57].
Results
We hypothesized that the phenotypic heterogeneity ob-
served in NDDs can be better understood by dissecting
the phenotype based on the pathways and modules dis-
rupted in these disorders. Given the high comorbidity of
NDDs, we tested the ability of MAGI-S to identify mod-
ules that can explain the association of specific genes to
distinct phenotypes. Focusing on the more common co-
morbid feature of seizures, we applied MAGI-S to a sub-
set of 111 seed genes strongly associated with NDDs,
producing 1 module per seed gene. The size of the mod-
ules (i.e., the number of genes in each module) ranged
from 25 to 79 genes, with an average size of 54 genes
per module (Additional file 1: Figure S2).
Significant enrichment of de novo mutations in
neurodevelopmental modules
We used a set of well-known neurodevelopmental disorder
genes as the input seed genes to MAGI-S for producing
relevant modules [28, 30–32]. We then investigated if the
identified modules as a whole were enriched with de novo
mutations found in the largest independent NDD studies in
denovo-db, including 8426 neurodevelopmental disorder
patients from (1) Simons Simplex Collection (SSC), (2)
MSSNG, and (3) Deciphering Developmental Disabilities
(DDD) 2017 cohorts relative to 1933 sibling/control sam-
ples (data from denovo-db version 1.6, Additional file 2:
Table S2: “denovo-db”) [27, 29, 43, 44, 58].
We compared the average number of loss-of-function
(LOF), missense, and synonymous de novo mutations
among probands and siblings/controls in the following
sets: (1) the seed genes (total of 111 genes), (2) the union
of all modules excluding seed genes (total of 1215
genes), (3) the union of all the genes in modules exclud-
ing the seed genes and 128 genes previously reported as
significantly associated with ASD, ID, or DD [28, 34, 37,
42, 59] (Additional file 2: Table S2: “established NDD
genes”) (a total of 1184 genes), and (4) all other genes
possessing de novo mutations outside of the union of all
constructed modules (total of 17,758 genes).
First, as expected, we observed a significant enrich-
ment of de novo variants in probands versus siblings for
the seed genes (p < 9.72e−52, p < 2.90e−12, and p < 1.68e
−57, for non-synonymous, missense, and LOF variants,
respectively) (Fig. 2). Second, more importantly, signifi-
cant enrichment was observed for de novo variants dis-
rupting the genes within these modules while excluding
the seed genes (p < 1.25e−10, p < 2.32e−6, and p < 1.74e
−8, for non-synonymous, missense, and LOF variants,
respectively). Third, we also observed a significant en-
richment of de novo mutations disrupting the union of
genes in modules after excluding the seed genes and
genes recently reported in the literature to be signifi-
cantly enriched with de novo variants in NDDs
(p < 2.67e−4, p < 3.35e−3, and p < 5.22e−3, for non-
synonymous, missense, and LOF variants, respectively).
We note that this indicates the set of genes identified in
these modules, even after removing the seed genes and
the known neurodevelopmental genes, is still enriched
for de novo variants in affected probands versus un-
affected siblings/controls. Thus, we conclude that the set
of genes in these modules should be enriched in novel
NDD genes. Finally, for the remaining set of 17,758
genes, we did not observe any significant difference in
de novo non-synonymous or synonymous variation be-
tween affected probands and unaffected siblings/controls
(Fig. 2). Due to an unequal ratio of cases (8426) to con-
trols (1933) sampled, we performed bootstrapping for
20,000 iterations per comparison to estimate the accur-
acy of the reported average number of mutations per in-
dividual (Additional file 1), finding the same pattern of
increased enrichment of de novo non-synonymous vari-
ation in cases relative to controls. We found that seed
genes contribute to the largest percentage of NDD diag-
nosis, followed by module genes, indicating that the
modules capture a significant proportion of de novo mu-
tations that affect NDDs even while excluding identified
ASD/ID/DD genes (Additional file 2: Table S2: “enrich-
ment (union)”).
We also compared the proportions of de novo muta-
tions associated with autism spectrum disorder (ASD)
[35–44], intellectual disability (ID) [46–49], developmental
disability (DD) [29], epilepsy [11, 45], and schizophrenia
(SCZ) [50–54] in genes inside and outside of each of the
111 modules independently. A total of 12,199 NDD pro-
bands and 1933 sibling/control samples were examined
(Additional file 2: Table S2: “denovo-db”) [58]. For mis-
sense and LOF variants annotated with ASD, ID, DD, or
epilepsy phenotypes, we evaluated the contingency tables
and observed that we have an odds ratio significantly
greater than 1 (with p < 0.05) for a large fraction of these
modules, indicating enrichment of de novo mutations in
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neurodevelopmental probands versus controls in each of
these modules (Additional file 2: Table S2). Resampling of
contingency tables by 5000 iterations of permutation test-
ing supports an increased enrichment of non-synonymous
de novo mutation in individual modules (Additional file 2:
Table S2: “contingency permutation”).
Dissection of epilepsy phenotype in neurodevelopmental
disorders using genetic modules
We next investigated the contribution of genetic mod-
ules in dissecting the epilepsy phenotype of NDDs. To
assess the relevance of each of these 111 modules, we
first measured the enrichment of de novo variants for
ASD, ID, DD, epilepsy, and SCZ cohorts disrupting the
modules selected for each of the seed genes (Fig. 3a).
When considering any type of non-synonymous de novo
variant associated with ASD, ID, DD, or epilepsy, we find
that 64 of the 111 modules show significant enrichment in
de novo non-synonymous mutations in these affected pro-
bands with neurodevelopmental disorders relative to un-
affected siblings/controls (Fig. 3a). This shows that most of
these modules (64/111 > 61%) are indeed significantly
enriched in de novo mutations observed in the neurodeve-
lopmental disorder probands versus unaffected siblings/
controls. Furthermore, we observed that almost all mod-
ules (100/111 > 90%) are enriched in coding copy number
variations (CNVs) that were detected via array comparative
genomic hybridization (aCGH) in probands with develop-
mental disorders relative to controls [60] (Additional file 2:
Table S2). Additionally, probands with de novo non-
synonymous mutations display (1) significantly lower ver-
bal, non-verbal, or full-scale IQ in 30 of 111 modules and
a b
c d
Fig. 2 Average number of non-synonymous and synonymous de novo mutations per individual for probands and controls in seed genes (Seed),
modules excluding seed genes (Module), module genes excluding 128 previously reported neurodevelopmental disorder genes (M-ND)
(Additional file 2: Table S2: “established NDD genes”), and genes outside of any module (Outside). a No significant difference in the number of
synonymous mutations exists between cases and controls. Cases display significantly more non-synonymous (b), including missense (c) and loss-
of-function (d), variants than controls in the Seed, Module, and M-ND groups
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Fig. 3 (See legend on next page.)
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(2) an enrichment in macrocephaly in 7 of 111 modules
relative to probands with de novo non-synonymous muta-
tions outside of the modules (Additional file 2: Table S2).
As expected, none of the modules are significantly
enriched in synonymous mutations in probands relative to
siblings/controls (Additional file 3: Table S3). In addition,
enrichment of de novo non-synonymous mutation in
cases relative to controls for each module was assessed for
penetrant missense mutations with CADD score greater
than 15 (Additional file 4: Table S2a), revealing increased
de novo mutation burden in cases relative to controls in
the union of all modules and in 64/111 individual modules
(Additional file 1: Figure S3S-4).
We next studied the capacity of these modules to dissect
the epilepsy phenotypes in neurodevelopmental disorders.
We investigated the enrichment of non-synonymous de
novo mutation in probands with either ASD/ID/DD or
epilepsy (E) phenotype relative to controls. We first com-
pared the odds ratio of de novo variants in ASD/ID/DD
cohorts for each module to the odds ratio of de novo vari-
ants from the epilepsy cohort (Fig. 3). Note that class 1
modules were constructed using neurodevelopmental seed
genes with high evidence of association to epilepsy based
on OMIM, DDG2P, and EpilepsyGene databases [28–32],
whereas class 3 modules were constructed using neurode-
velopmental seed genes with minimal evidence of associ-
ation with epilepsy in these databases. We compared the
odds ratio of de novo variants observed in probands ver-
sus controls separately for the (1) ASD/ID/DD cohort and
(2) the epilepsy cohort for each of the modules (Fig. 3b).
The odds ratio for the ASD/ID/DD cohort is significantly
greater than expected (p < 0.05) for 62 of 111 modules
from all three classes. Similar fraction of modules from
classes 1, 2, and 3 had a higher than expected odds ratio
for de novo mutations in the ASD/ID/DD cohort (19/
35 > 54%, 13/21 > 61%, 30/55 > 54%, respectively).
On the other hand, a much larger fraction of modules
from class 1 (31/35 > 89%) had significantly greater than
expected odds ratio for the de novo mutations in the
epilepsy cohort (Fig. 3b). In contrast, the fraction of
modules significantly enriched for de novo mutations is
almost the same between ASD/ID/DDD and epilepsy co-
horts for class 3 modules (Fig. 3b).
We also compared the average odds ratio of modules
for de novo non-synonymous variants in probands from
the epilepsy cohort versus siblings/controls for modules
in class 1, class 2, and class 3 (Fig. 3c). We observed a
significantly higher average odds ratio for de novo vari-
ants in the epilepsy cohort for modules in class 1 com-
pared with class 3 (p < 2.22e−5). These results support
the hypothesis that modules predicted using seed genes
can help in dissecting the epilepsy phenotype in neuro-
developmental disorders (Fig. 3b, c).
Epilepsy genes enriched in modules built using class 1 seed
genes
To investigate the ability of modules to dissect epilepsy
phenotypes, we assessed the enrichment of the epilepsy
genes in the modules predicted by MAGI-S. Modules
seeded with genes from class 1 gene set contain a signifi-
cantly higher number of genes previously reported to be
associated with epilepsy (Additional file 1) than modules
found using seed genes from either class 2 or class 3
gene sets (Fig. 4) [28, 30, 32, 33]. Similarly, the average
number of genes associated with epilepsy in class 1
modules was significantly higher than that in class 2 or
class 3 modules (p < 8.21e−3 and p < 4.63e−8, respect-
ively). Genes most frequently shared among class 1
modules (such as DLG4, GRIN2A, PRKCB, and SNAP25)
have been associated with epilepsy, synaptic function,
and neuronal processes [61–64].
Modules show enrichment in neuronal and epileptic
processes
To assess the biological relevance of the identified mod-
ules, we analyzed the Gene Ontology (GO) and Reactome
pathway enrichment for genes in each of the modules. The
study of genetic modules disrupted in NDDs enables the
identification of biological processes and functions that
most contribute to these disorders. Enrichments from class
1 and class 2 modules indicate processes relevant to epi-
lepsy and seizures, including GABAergic, cholinergic,
dopaminergic, glycinergic, noradrenergic, and serotonergic
synaptic transmission, and postsynaptic, excitatory, and in-
hibitory chemical synaptic transmission (Additional file 5:
Table S4) [55].
Most modules (22/27 > 81%) that contained a large
proportion of genes associated with epilepsy (enrichment
score greater than 7.5) were enriched in chemical synap-
tic transmission pathways (Additional file 1: Figure S5).
(See figure on previous page.)
Fig. 3 Summary of significant enrichment in de novo mutation and copy number variation (CNV) overlap in neurodevelopmental modules.
Modules are grouped by class to indicate the degree of association of the seed gene with the epilepsy phenotype. Class 1, class 2, and class 3
modules correspond to the seed genes that have strong, moderate, and weak evidence of association with epilepsy, respectively. a Significant
enrichment of missense (miss.) and loss-of-function (LOF) mutations for autism spectrum (ASD), intellectual disability (ID), developmental disability
(DD), epilepsy (E), and schizophrenia cohorts within modules. b Comparison of log2 of significant (p < 0.05) enrichment of de novo mutation for
variants annotated as ASD/ID/DD (left) or epilepsy (right). c Average odds ratio of de novo mutations annotated in epilepsy cases relative to
controls is significantly greater in class 1 modules compared to class 3 modules
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On the other hand, all remaining modules were enriched
for genes related to chromatin regulation and or axon
guidance.
Furthermore, many of class 1 and class 2 modules (33/
56 > 58%) were enriched for interleukin signaling (p <
0.0001), which has been previously associated with epi-
lepsy, and the MAPK, Ras, and VEGFR2 signaling path-
ways [65–70] (Additional file 1: Figure S6). Notch and
TGF-beta signaling pathways were primarily enriched in
class 2 and class 3 modules.
Using Enrichr analysis [56], we found that most (18/
35 > 51%) class 1 modules are enriched for genes signifi-
cantly associated with the OMIM disease terms “epi-
lepsy,” “seizures,” or “ataxia.” Conversely, the genes that
occur most commonly in class 3 modules (UBC, EP300,
SMAD2, CSNK2A1, and ABL1) are associated with aut-
ism and/or intellectual disability [62, 71–73], and most
(44/55 = 80%) class 3 modules are enriched for genes
associated with the term “autism” (Additional file 5:
Table S4). We believe these results support the hypoth-
esis that modules and networks can be utilized to dissect
the phenotypic heterogeneity observed in NDDs.
Selective expression of specific cell types and regulation
in neurodevelopmental modules
We also sought to use our modules to pinpoint the
neuronal critical cell types involved with specific neuro-
developmental disorder phenotypes. Knowing the neur-
onal cell types involved would help further study of gene
expression dysregulation in those cell types in affected
patients. We observed that most modules from class 1
are selectively expressed in layer 5 and 6 cortical neu-
rons and D1+ and D2+ spiny neurons in the striatum.
This is also true for the union of the genes in all class 1
modules (Fig. 5), according to the cell type-specific ex-
pression analyses (CSEA) tool that uses RNAseq data
a b
Fig. 4 Phenotypic enrichment of genes in modules while including the seed gene. Enrichment is defined (MP/MP′)/(GP/(19,986 − GP)), where MP is
the number of genes annotated as a certain neurodevelopmental disorder (NDD) phenotype inside a module, MP′ is the complement of MP, and
GP is the total number of genes annotated as a certain phenotype. The total number of genes in the human genome is 19,986 (Gencode
GRCh38.p12). Increased enrichment of NDD with or without epilepsy for a module corresponds respectively to the presence or absence of
epilepsy phenotypes associated with the seed gene. Modules are grouped by evidence of epilepsy association of the seed genes—i.e., class 1
(strong), class 2 (moderate), and class 3 (weak association). a Increased enrichment of NDDs with epilepsy observed in class 1 modules are
indicated by an increased y-intercept of class 1 regression line relative to class 2 and class 3. b Average enrichment of NDD with epilepsy is
significantly greater in class 1 modules compared to class 2 or class 3 modules
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from BrainSpan [57]. Furthermore, genes in class 1 mod-
ules show expression in early infancy to young adult-
hood in the developing brain, whereas genes in class 2
and class 3 modules separately are expressed primarily
during fetal stages of development. Additionally, class 1
modules are enriched specifically in the brain relative to
other tissues, which complements the enrichment of
pathways involved in growth and development in class 3
modules (Additional file 1: Figure S7, Additional file 6:
Table S5).
Discussion
We have applied MAGI-S to construct modules from
seed genes relevant to NDDs with and without associ-
ation with epileptic phenotypes. The high degree of plei-
otropy that exists among NDD genes complicates the
understanding of the role of candidate genes in neurode-
velopment. However, the ability to dissect the specific
epilepsy phenotype from more general, heterogenous
NDD phenotypes enables the improved characterization
of candidate NDD genes in relation to specific NDD
subtypes. To dissect specific phenotypes from a more
general phenotype, the choice of seed genes with varied
degrees of association with the specific phenotype of
interest is critical to module discovery. MAGI-S pro-
duces modules that are highly co-expressed with the
seed gene. Thus, we investigated the hypothesis that the
selection of seed genes that are strongly associated with
epilepsy would produce modules that participate in
pathways that underlie the epilepsy phenotype. Seed
genes were selected from the aggregation of different,
large-scale studies, including whole-genome and whole-
exome sequencing studies. It is important to note that
the selected seed genes have a significant impact on the
modules found by MAGI-S. To construct modules in a
spatio-temporal context, we chose to use the BrainSpan
Atlas that describes the gene co-expression in the devel-
oping human brain at a range of life stages [25]. Critical
processes that underlie typical neurodevelopment are
performed by co-expressed genes that may be vulnerable
Fig. 5 Cell type-specific expression analyses (CSEA) profile for the union of class 1 modules. Transcripts from provided gene lists that overlap
significantly in specific cell types are indicated by intensity of color. Modules with seed genes strongly associated with epilepsy (class 1) show
selective expression in the cortical neurons and spiny neurons in the striatum
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to deleterious mutation and are thus relevant to NDDs
[74, 75]. As co-expression resources for affected pro-
bands at varying developmental stages are developed,
modules constructed by MAGI-S will be able to more
accurately reflect pathway dysregulation over time.
Genes that occur frequently and exclusively in class 1 or
class 2 module groups point to potential novel candidate
genes, such as DLG4, PRKCB, STX1A, and YWHAH, that
may play important roles in NDDs with epileptic pheno-
types. Among the genes that have not previously been
defined as epilepsy genes, DLG4 is the most commonly
shared gene among class 1 modules and has been impli-
cated in autism, intellectual disability, and synaptic func-
tion [76, 77]. PRKCB is a candidate gene for partial
epilepsies and possibly involved in microRNA dysregula-
tion in patients with mesial temporal lobe epilepsy [63, 78].
STX1A is a presynaptic gene to which its paralog STXBP1
binds to regulate the SNARE complex, associated with epi-
lepsy [79], and STX1A knockout mice experience reduced
dense-core vesicle exocytosis and abnormal monoaminer-
gic transmission [80]. YWHAx genes, including YWHAH,
have been hypothesized to be involved in neurological dis-
orders including familial partial epilepsy [81, 82]. Genes
that occur frequently in class 3 modules but are absent in
class 1 modules such as MYC and SIRT1 are implicated in
tumorigenesis and metabolism [83, 84]; SIRT1 is involved
in learning and memory [85].
An accumulation of de novo missense and LOF muta-
tions contribute to the manifestation of several NDDs
[35, 86]. We found that most modules have significantly
more de novo mutations in NDD probands than in con-
trols (Fig. 2, Additional file 2: Table S2), and 88% of class
1 modules are significantly enriched in epilepsy cohort-
specific variants relative to controls. However, the poten-
tially high degree of comorbidity among NDD probands
and pleiotropy in NDDs suggests that particular de novo
variants may impart the risk on several NDD pheno-
types, although full comorbid phenotype information is
not available from denovo-db. Thus, the enrichment of
cohort-specific variants may not capture all genetic vari-
ation associated with a specific NDD phenotype, such as
epilepsy. Analyses which concern all NDD-associated vari-
ants, such as the enrichment of de novo mutation within
modules, are not dependent on phenotypic annotation and
reflect the diversity of NDD phenotypes that may associate
with seed genes and module genes. Seed genes and the
union of all modules excluding seed genes capture a large
proportion (~ 46%) of the de novo mutation signal that
contributes to NDDs (Fig. 2, Additional file 2: Table S2:
“enrichment (union)”). We observed that the union of
genes identified in the modules is significantly enriched in
de novo variants in NDD probands versus siblings/con-
trols. This enrichment was still true after removing genes
that were previously reported to be significantly enriched
in de novo variants in these disorders (Additional file 2:
Table S2: “established NDD genes”). However, we did not
observe a significant difference between the genes not
found in any module (17,758 genes) for de novo variants in
NDDs versus siblings/controls. We believe this supports a
polygenic model for de novo variation in NDDs, in which
mutations accumulate in genes that modulate pathways
that underlie complex disease, in comparison with an
omnigenic model, in which disease-associated signals are
widespread across the genome. The penetrance of rare
genetic variation may also be affected by common variation
to result in a wide phenotypic heterogeneity among NDDs
with typically monogenic forms [87]. Additionally, the
overlap of coding CNVs with individual modules, con-
firmed via permutation tests, indicates that there is a sig-
nificantly greater proportion of CNVs that overlap genes
inside modules in probands than in controls, suggesting
that copy number variation of genes within modules may
also disrupt normal neurodevelopmental function.
We assessed the relevance of modules by comparing
enrichments in biological processes, signaling pathways,
and selective expression in the human brain during dif-
ferent developmental stages. Modules seeded with genes
that are strongly associated with epilepsy tend to cluster
more distinctly than other module groups in relation to
GO biological processes and Reactome pathways [55]
(Additional file 1: Figure S5, Additional file 1: Figure S6).
Most modules seeded with epilepsy genes are strongly re-
lated to chemical synaptic transmission, while modules pro-
duced with seed genes associated with other NDDs without
epileptic phenotypes are related to chromatin organization
and regulation, suggesting that the biological processes of a
module correspond to its respective seed gene. Indeed,
genome-wide analyses have previously associated autism
genes with chromatin regulation [42, 59, 88, 89]. Class 1 and
class 2 modules that have NDD with epilepsy enrichment
scores consistently greater than 7.5 are enriched in similar
biological processes involving chemical synaptic transmis-
sion and are selectively expressed in deep cortical neurons
and spiny neurons in the striatum, which may indicate a
stronger role of certain class 2 seed genes in epilepsy than
previously suggested. The selective expression of class 1
modules in layer 5 and 6 cortical neurons is consistent with
the epilepsy phenotype. Loss of excitatory neurons and the
initiation of epileptic discharge have been observed in deep
cortical layers, including layers 5 and 6, in individuals with
epilepsy [90–92]. Additionally, in the striatum, direct and in-
direct neural pathways respectively modulate motor func-
tion via dopamine receptors D1 and D2 [93–95].
Conclusion
We have constructed modules of high connectivity rele-
vant to NDDs. The choice of gene used for seed module
construction is critical to module formation. To minimize
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bias in selecting seed genes, we selected all high confi-
dence and strong candidate NDD genes curated from
multiple, high-quality whole-exome and genome sequen-
cing studies as per the SFARI Gene database and all genes
that have been reported to be concurrently associated with
epilepsy according to OMIM, DDG2P, EpilepsyGene, and
a recent review [28, 30–32]. From our choices of seed
genes, we describe three general classes of modules by the
strength of evidence of epilepsy association. We find that
the majority of modules are significantly enriched in de
novo mutations, and modules constructed with seed genes
that are strongly associated with epilepsy tend to be (1)
significantly enriched in de novo mutation from individ-
uals affected by epilepsy relative to unaffected controls, (2)
enriched in epilepsy-associated genes, and (3) enriched for
biological function relevant to seizure. Genes with de novo
mutations that have not been traditionally associated with
NDDs but are present in modules constructed from rele-
vant seed genes could play an important role in disease.
Furthermore, MAGI-S may be applied to dissect the gen-
etic complexity of other diseases characterized by specific
clinical features and identify candidate genes in diseases
with strong de novo mutation components. The seed-
centric approach to module discovery integrates inter-
action networks and identifies a core set of genes strongly
associated with phenotypes attributed to the seed gene
and supported by biological evidence.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13073-019-0678-y.
Additional file 1: Supplementary methods, Figure S1-S7, and Table S1.
Additional file 2: Table S2. Summary of analyses performed per
module, including determinations of enrichment of de novo mutation,
overlap with coding copy number variations. Module membership and
frequency of occurrence for all genes selected in any module are
displayed in the ‘modules’ tab. Number of cases and controls for ASD, ID,
DD, and epilepsy cohorts within denovo-db are displayed in the ‘denovo-
db’ tab. Contingency tables for Fisher’s exact test were constructed to
assess the enrichment of de novo mutation and copy number variations
in modules. Contingency table permutation empirical p-values are
displayed in the ‘contingency permutations’ tab. Percent contribution to
neurodevelopmental disorder diagnoses and comparison of average
number of mutations per individual are displayed in the ‘enrichment
(union)’ tab. Tabs corresponding to a module name show the total
number of de novo variants, associated phenotype, type of variant, and
neurodevelopmental disorder-related descriptions per module.
Additional file 3: Table S3. Proportions of synonymous mutations in
neurodevelopmental cases relative to controls. Tabs correspond to
modules and respective total number of synonymous de novo variants.
Additional file 4: Table S2a. Similar to Additional file 2: Table S2,
Additional file 4: Table S2a displays a summary of analyses performed per
module while requiring a CADD score greater than 15 for missense
variants.
Additional file 5: Table S4. Significant GO terms, KEGG, and Reactome
pathway enrichments, and OMIM disease terms per module (p-value < 0.05).
Additional file 6: Contains Table S5. Selective expression profiles for
union of modules based on strength of epilepsy association (Classes 1, 2,
and 3 as C1, C2, and C3, respectively), including: Cell-type specific Expression
Analyses (CSEA), Specific Expression Analyses (SEA) for adult brain regions
and development, and Tissue-Specific Expression Analyses (TSEA).
Abbreviations
NDD: Neurodevelopmental disorder; ASD: Autism spectrum disorder;
DD: Developmental disability/disorder; ID: Intellectual disability;
SCZ: Schizophrenia; LOF: Loss-of-function; CNV: Copy number variation;
SSC: Simons Simplex Collection; DDD: Deciphering Developmental Disorders;
ASC: Autism Sequencing Consortium; CSEA: Cell-type specific expression
analysis; SEA: Specific expression analysis; TSEA: Tissue-specific expression
analysis
Acknowledgements
We would like to thank the anonymous reviewers for the helpful comments
and suggestions.
Authors’ contributions
FH and OP wrote the MAGI. JC and FH implemented the MAGI-S to produce
modules. JC analyzed the data and created all the figures and tables. JC, HA,
FH, SG, MJ, and SS wrote the manuscript. All authors read and approved the
final manuscript.
Funding
This work is funded in part by the Sloan Research Fellowship FG-2017-9159
and UC-Davis funding to FH and NIH R01-GM121907, SFARI Pilot Grant (SFARI
399894, SG), and resources from the Huck Institutes of the Life Sciences to
SG. MJ was supported by NIH T32-GM102057.
Availability of data and materials
denovo-db (version 1.6) is available at http://denovo-db.gs.washington.edu/
denovo-db/. SFARI gene scores are available at https://gene.sfari.org/
database/gene-scoring/. OMIM annotations are available at https://www.
omim.org. DDG2P annotations are available at https://decipher.sanger.ac.uk/
ddd#ddgenes. Enrichr is hosted at https://amp.pharm.mssm.edu/Enrichr/.
CSEA, SEA, and TSEA tools are available at http://genetics.wustl.edu/jdlab/
csea-tool-2/. MAGI source code, PPI network, co-expression hash tables and
dataset, and control mutations are available at https://eichlerlab.gs.washing-
ton.edu/MAGI/. MAGI-S source code is available at https://github.com/
jchow32/magi-s.
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
OP is employed by MyHeritage, but this does not form a competing interest.
The remaining authors also declare that they have no competing interests.
Author details
1UC Davis Genome Center, University of California, Davis, USA.
2Bioinformatics and Genomics Graduate Program, The Huck Institutes of the
Life Sciences, Pennsylvania State University, University Park, USA.
3Department of Neurology, School of Medicine, University of California,
Davis, USA. 4T.H. Chan School of Public Health, Harvard University, Boston,
USA. 5MyHeritage, 6037606 Or Yehuda, Israel. 6Department of Genetics, The
Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem,
Israel. 7Department of Biochemistry and Molecular Biology, Pennsylvania
State University, University Park, USA. 8MIND Institute, University of California,
Davis, USA. 9Biochemistry and Molecular Medicine, University of California,
Davis, USA.
Received: 28 July 2019 Accepted: 15 October 2019
References
1. Geschwind DH, Levitt P. Autism spectrum disorders: developmental
disconnection syndromes. Curr Opin Neurobiol. 2007;17(1):103–11.
Chow et al. Genome Medicine           (2019) 11:65 Page 12 of 14
2. Tuchman R, Rapin I. Epilepsy in autism. Lancet Neurol. 2002;1(6):352–8.
3. Amiet C, Gourfinkel-An I, Bouzamondo A, Tordjman S, Baulac M, Lechat P,
et al. Epilepsy in autism is associated with intellectual disability and gender:
evidence from a meta-analysis. Biol Psychiatry. 2008;64(7):577–82.
4. Polyak A, Rosenfeld JA, Girirajan S. An assessment of sex bias in
neurodevelopmental disorders. Genome Med. 2015;7:94.
5. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T, et al. Strong
association of de novo copy number mutations with autism. Science. 2007;
316(5823):445–9.
6. O’Roak BJ, Deriziotis P, Lee C, Vives L, Schwartz JJ, Girirajan S, et al. Exome
sequencing in sporadic autism spectrum disorders identifies severe de novo
mutations. Nat Genet. 2011;43(6):585–U125.
7. Weiss LA, Escayg A, Kearney JA, Trudeau M, MacDonald BT, Mori M, et al.
Sodium channels SCN1A, SCN2A and SCN3A in familial autism. Mol
Psychiatry. 2003;8(2):186–94.
8. Shi X, Yasumoto S, Nakagawa E, Fukasawa T, Uchiya S, Hirose S. Missense
mutation of the sodium channel gene SCN2A causes Dravet syndrome.
Brain and Development. 2009;31(10):758–62.
9. Ching MS, Shen Y, Tan WH, Jeste SS, Morrow EM, Chen X, et al. Deletions of
NRXN1 (neurexin-1) predispose to a wide spectrum of developmental
disorders. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(4):937–47.
10. Harrison V, Connell L, Hayesmoore J, McParland J, Pike MG, Blair E.
Compound heterozygous deletion of NRXN1 causing severe developmental
delay with early onset epilepsy in two sisters. Am J Med Genet A. 2011;
155A(11):2826–31.
11. Epi KC, Epilepsy Phenome/Genome P, Allen AS, Berkovic SF, Cossette P,
Delanty N, et al. De novo mutations in epileptic encephalopathies. Nature.
2013;501(7466):217–21.
12. Mefford HC, Muhle H, Ostertag P, von Spiczak S, Buysse K, Baker C, et al.
Genome-wide copy number variation in epilepsy: novel susceptibility loci in
idiopathic generalized and focal epilepsies. PLoS Genet. 2010;6(5):e1000962.
13. Gonzalez-Mantilla AJ, Moreno-De-Luca A, Ledbetter DH, Martin CL. A cross-
disorder method to identify novel candidate genes for developmental brain
disorders. JAMA Psychiatry. 2016;73(3):275–83.
14. Jensen M, Girirajan S. Mapping a shared genetic basis for
neurodevelopmental disorders. Genome Med. 2017;9(1):109.
15. Gilman SR, Iossifov I, Levy D, Ronemus M, Wigler M, Vitkup D. Rare de novo
variants associated with autism implicate a large functional network of
genes involved in formation and function of synapses. Neuron. 2011;70(5):
898–907.
16. Hormozdiari F, Penn O, Borenstein E, Eichler EE. The discovery of integrated
gene networks for autism and related disorders. Genome Res. 2015;25(1):
142–54.
17. Krishnan A, Zhang R, Yao V, Theesfeld CL, Wong AK, Tadych A, et al.
Genome-wide prediction and functional characterization of the genetic
basis of autism spectrum disorder. Nat Neurosci. 2016;19(11):1454–62.
18. Liu L, Lei J, Sanders SJ, Willsey AJ, Kou Y, Cicek AE, et al. DAWN: a
framework to identify autism genes and subnetworks using gene
expression and genetics. Mol Autism. 2014;5(1):22.
19. O’Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, et al. Sporadic
autism exomes reveal a highly interconnected protein network of de novo
mutations. Nature. 2012;485(7397):246–50.
20. Parikshak NN, Luo R, Zhang A, Won H, Lowe JK, Chandran V, et al.
Integrative functional genomic analyses implicate specific molecular
pathways and circuits in autism. Cell. 2013;155(5):1008–21.
21. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al.
The GeneMANIA prediction server: biological network integration for gene
prioritization and predicting gene function. Nucleic Acids Res. 2010;38(Web
Server issue):W214–20.
22. Vandin F, Upfal E, Raphael BJ. De novo discovery of mutated driver
pathways in cancer. Genome Res. 2012;22(2):375–85.
23. Vandin F, Upfal E, Raphael BJ. Algorithms for detecting significantly mutated
pathways in cancer. J Comput Biol. 2011;18(3):507–22.
24. Jeste SS, Geschwind DH. Disentangling the heterogeneity of autism spectrum
disorder through genetic findings. Nat Rev Neurol. 2014;10(2):74–81.
25. Sunkin SM, Ng L, Lau C, Dolbeare T, Gilbert TL, Thompson CL, et al. Allen
Brain Atlas: an integrated spatio-temporal portal for exploring the central
nervous system. Nucleic Acids Res. 2013;41(Database issue):D996–D1008.
26. Prasad TSK, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S,
et al. Human Protein Reference Database-2009 update. Nucleic Acids Res.
2009;37:D767–D72.
27. Turner TN, Yi Q, Krumm N, Huddleston J, Hoekzema K, Stessman HAF, et al.
NAR breakthrough article denovo-db: a compendium of human de novo
variants. Nucleic Acids Res. 2017;45(D1):D804–D11.
28. Abrahams BS, Arking DE, Campbell DB, Mefford HC, Morrow EM, Weiss LA,
et al. SFARI Gene 2.0: a community-driven knowledgebase for the autism
spectrum disorders (ASDs). Mol Autism. 2013;4:36.
29. Deciphering Developmental Disorders S. Prevalence and architecture of de
novo mutations in developmental disorders. Nature. 2017;542(7642):433–8.
30. Ran X, Li J, Shao Q, Chen H, Lin Z, Sun ZS, et al. EpilepsyGene: a genetic
resource for genes and mutations related to epilepsy. Nucleic Acids Res.
2015;43(Database issue):D893–9.
31. Wang J, Lin ZJ, Liu L, Xu HQ, Shi YW, Yi YH, et al. Epilepsy-associated genes.
Seizure. 2017;44:11–20.
32. Wright CF, Fitzgerald TW, Jones WD, Clayton S, Mcrae JF, van Kogelenberg M,
et al. Genetic diagnosis of developmental disorders in the DDD study: a scalable
analysis of genome-wide research data. Lancet. 2015;385(9975):1305–14.
33. Berkovic S, Cossette P, Delanty N, Dlugos D, Eichler E, Epstein M, et al. Epi4K:
gene discovery in 4,000 genomes. Epilepsia. 2012;53(8):1457–67.
34. Mcrae JF, Clayton S, Fitzgerald TW, Kaplanis J, Prigmore E, Rajan D, et al.
Prevalence and architecture of de novo mutations in developmental
disorders. Nature. 2017;542(7642):433.
35. Iossifov I, O’Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, et al. The
contribution of de novo coding mutations to autism spectrum disorder.
Nature. 2014;515(7526):216–U136.
36. Krumm N, Turner TN, Baker C, Vives L, Mohajeri K, Witherspoon K, et al.
Excess of rare, inherited truncating mutations in autism. Nat Genet. 2015;
47(6):582–8.
37. O’Roak BJ, Stessman HA, Boyle EA, Witherspoon KT, Martin B, Lee C, et al.
Recurrent de novo mutations implicate novel genes underlying simplex
autism risk. Nat Commun. 2014;5:5595.
38. O’Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, et al. Multiplex
targeted sequencing identifies recurrently mutated genes in autism
spectrum disorders. Science. 2012;338(6114):1619–22.
39. Turner TN, Coe BP, Dickel DE, Hoekzema K, Nelson BJ, Zody MC, et al.
Genomic patterns of de novo mutation in simplex autism. Cell. 2017;171(3):
710–22 e12.
40. Turner TN, Hormozdiari F, Duyzend MH, McClymont SA, Hook PW, Iossifov I,
et al. Genome sequencing of autism-affected families reveals disruption of
putative noncoding regulatory DNA. Am J Hum Genet. 2016;98(1):58–74.
41. Werling DM, Brand H, An JY, Stone MR, Zhu L, Glessner JT, et al. An
analytical framework for whole-genome sequence association studies and
its implications for autism spectrum disorder. Nat Genet. 2018;50(5):727–36.
42. De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al.
Synaptic, transcriptional and chromatin genes disrupted in autism. Nature.
2014;515(7526):209–U119.
43. Yuen RK, Merico D, Cao H, Pellecchia G, Alipanahi B, Thiruvahindrapuram B,
et al. Genome-wide characteristics of de novo mutations in autism. NPJ
Genom Med. 2016;1:160271–1602710.
44. Yuen RKC, Merico D, Bookman M, Howe JL, Thiruvahindrapuram B, Patel RV,
et al. Whole genome sequencing resource identifies 18 new candidate
genes for autism spectrum disorder. Nat Neurosci. 2017;20(4):602.
45. Helbig KL, Farwell Hagman KD, Shinde DN, Mroske C, Powis Z, Li S,
et al. Diagnostic exome sequencing provides a molecular diagnosis for
a significant proportion of patients with epilepsy. Genet Med. 2016;
18(9):898–905.
46. de Ligt J, Willemsen MH, van Bon BW, Kleefstra T, Yntema HG, Kroes T, et al.
Diagnostic exome sequencing in persons with severe intellectual disability.
N Engl J Med. 2012;367(20):1921–9.
47. Halvardson J, Zhao JJ, Zaghlool A, Wentzel C, Georgii-Hemming P, Mansson
E, et al. Mutations in HECW2 are associated with intellectual disability and
epilepsy. J Med Genet. 2016;53(10):697–704.
48. Rauch A, Wieczorek D, Graf E, Wieland T, Endele S, Schwarzmayr T, et al.
Range of genetic mutations associated with severe non-syndromic sporadic
intellectual disability: an exome sequencing study. Lancet. 2012;380(9854):
1674–82.
49. Lelieveld SH, Reijnders MR, Pfundt R, Yntema HG, Kamsteeg EJ, de Vries P,
et al. Meta-analysis of 2,104 trios provides support for 10 new genes for
intellectual disability. Nat Neurosci. 2016;19(9):1194–6.
50. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P,
et al. De novo mutations in schizophrenia implicate synaptic networks.
Nature. 2014;506(7487):179–84.
Chow et al. Genome Medicine           (2019) 11:65 Page 13 of 14
51. Gulsuner S, Walsh T, Watts AC, Lee MK, Thornton AM, Casadei S, et al.
Spatial and temporal mapping of de novo mutations in schizophrenia to a
fetal prefrontal cortical network. Cell. 2013;154(3):518–29.
52. Kranz TM, Harroch S, Manor O, Lichtenberg P, Friedlander Y, Seandel M,
et al. De novo mutations from sporadic schizophrenia cases highlight
important signaling genes in an independent sample. Schizophr Res. 2015;
166(1–3):119–24.
53. McCarthy SE, Gillis J, Kramer M, Lihm J, Yoon S, Berstein Y, et al. De novo
mutations in schizophrenia implicate chromatin remodeling and support a
genetic overlap with autism and intellectual disability. Mol Psychiatry. 2014;
19(6):652–8.
54. Smedemark-Margulies N, Brownstein CA, Vargas S, Tembulkar SK, Towne
MC, Shi J, et al. A novel de novo mutation in ATP1A3 and childhood-onset
schizophrenia. Cold Spring Harb Mol Case Stud. 2016;2(5):a001008.
55. Fabregat A, Sidiropoulos K, Garapati P, Gillespie M, Hausmann K, Haw R,
et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 2016;
44(D1):D481–D7.
56. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al.
Enrichr: a comprehensive gene set enrichment analysis web server 2016
update. Nucleic Acids Res. 2016;44(W1):W90–7.
57. Xu XX, Wells AB, O’Brien DR, Nehorai A, Dougherty JD. Cell type-specific
expression analysis to identify putative cellular mechanisms for
neurogenetic disorders. J Neurosci. 2014;34(4):1420–31.
58. Fischbach GD, Lord C. The Simons Simplex Collection: a resource for
identification of autism genetic risk factors. Neuron. 2010;68(2):192–5.
59. Sanders SJ, Xin H, Willsey AJ, Ercan-Sencicek AG, Samocha KE, Cicek AE,
et al. Insights into autism spectrum disorder genomic architecture and
biology from 71 risk loci. Neuron. 2015;87(6):1215–33.
60. Coe BP, Witherspoon K, Rosenfeld JA, van Bon BWM, Vulto-van Silfhout AT,
Bosco P, et al. Refining analyses of copy number variation identifies specific
genes associated with developmental delay. Nat Genet. 2014;46(10):1063–
71.
61. Addis L, Virdee JK, Vidler LR, Collier DA, Pal DK, Ursu D. Epilepsy-associated
GRIN2A mutations reduce NMDA receptor trafficking and agonist potency -
molecular profiling and functional rescue. Sci Rep-Uk. 2017;7:66.
62. Crawley JN, Heyer WD, LaSalle JM. Autism and cancer share risk genes,
pathways, and drug targets. Trends Genet. 2016;32(3):139–46.
63. Danis B, van Rikxoort M, Kretschmann A, Zhang J, Godard P, Andonovic L,
et al. Differential expression of miR-184 in temporal lobe epilepsy patients
with and without hippocampal sclerosis - influence on microglial function.
Sci Rep. 2016;6:33943.
64. Rohena L, Neidich J, Cho MT, Gonzalez KDF, Tang S, Devinsky O, et al.
Mutation in SNAP25 as a novel genetic cause of epilepsy and intellectual
disability. Rare Dis. 2015;1:e26314.
65. Goines P, Van de Water J. The immune system’s role in the biology of
autism. Curr Opin Neurol. 2010;23(2):111–7.
66. Griffin WST, Yeralan O, Sheng JG, Boop FA, Mrak RE, Rovnaghi CR, et al.
Overexpression of the neurotrophic cytokine S100-beta in human temporal-
lobe epilepsy. J Neurochem. 1995;65(1):228–33.
67. Lee C, Agoston DV. Inhibition of VEGF receptor 2 increased cell death of
dentate hilar neurons after traumatic brain injury. Exp Neurol. 2009;220(2):
400–3.
68. Maroso M, Balosso S, Ravizza T, Liu J, Bianchi ME, Vezzani A. Interleukin-1
type 1 receptor/Toll-like receptor signalling in epilepsy: the importance of
IL-1beta and high-mobility group box 1. J Intern Med. 2011;270(4):319–26.
69. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in
epilepsy. Nat Rev Neurol. 2011;7(1):31–40.
70. Vezzani A, Maroso M, Balosso S, Sanchez MA, Bartfai T. IL-1 receptor/Toll-like
receptor signaling in infection, inflammation, stress and neurodegeneration
couples hyperexcitability and seizures. Brain Behav Immun. 2011;25(7):1281–9.
71. Kaufman L, Ayub M, Vincent JB. The genetic basis of non-syndromic
intellectual disability: a review. J Neurodev Disord. 2010;2(4):182–209.
72. Okur V, Cho MT, Henderson L, Retterer K, Schneider M, Sattler S, et al. De
novo mutations in CSNK2A1 are associated with neurodevelopmental
abnormalities and dysmorphic features. Hum Genet. 2016;135(7):699–705.
73. Wincent J, Luthman A, van Belzen M, van der Lans C, Albert J, Nordgren A,
et al. CREBBP and EP300 mutational spectrum and clinical presentations in a
cohort of Swedish patients with Rubinstein-Taybi syndrome EP300
mutational spectrum and clinical presentations in a cohort of Swedish
patients with Rubinstein-Taybi syndrome (vol 4, pg 39, 2016). Mol Genet
Genom Med. 2016;4(3):367
74. Andersen SL. Trajectories of brain development: point of vulnerability or
window of opportunity? Neurosci Biobehav Rev. 2003;27(1–2):3–18.
75. Willsey AJ, Sanders SJ, Li M, Dong S, Tebbenkamp AT, Muhle RA, et al.
Coexpression networks implicate human midfetal deep cortical projection
neurons in the pathogenesis of autism. Cell. 2013;155(5):997–1007.
76. Feyder M, Karlsson RM, Mathur P, Lyman M, Bock R, Momenan R, et al.
Association of mouse Dlg4 (PSD-95) gene deletion and human DLG4 gene
variation with phenotypes relevant to autism spectrum disorders and
Williams’ syndrome. Am J Psychiat. 2010;167(12):1508–17.
77. Krishnan ML, Van Steenwinckel J, Schang AL, Yan J, Arnadottir J, Le
Charpentier T, et al. Integrative genomics of microglia implicates DLG4
(PSD95) in the white matter development of preterm infants. Nat Commun.
2017;8:428.
78. Kasperaviciute D, Catarino CB, Heinzen EL, Depondt C, Cavalleri GL, Caboclo
LO, et al. Common genetic variation and susceptibility to partial epilepsies:
a genome-wide association study. Brain. 2010;133:2136–47.
79. Gerber SH, Rah JC, Min SW, Liu XR, de Wit H, Dulubova I, et al.
Conformational switch of syntaxin-1 controls synaptic vesicle fusion.
Science. 2008;321(5895):1507–10.
80. Fujiwara T, Kofuji T, Akagawa K. Dysfunction of the hypothalamic-
pituitary-adrenal axis in STX1A knockout mice. J Neuroendocrinol. 2011;
23(12):1222–30.
81. Foote M, Zhou Y. 14-3-3 proteins in neurological disorders. Int J Biochem
Mol Biol. 2012;3(2):152–64.
82. Morales-Corraliza J, Gomez-Garre P, Sanz R, Diaz-Otero F, Gutierrez-Delicado
E, Serratosa JM. Familial partial epilepsy with variable foci: a new family with
suggestion of linkage to chromosome 22q12. Epilepsia. 2010;51(9):1910–4.
83. Dang CV. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring
Harb Perspect Med. 2013;3(8):a014217.
84. Song NY, Surh YJ. Janus-faced role of SIRT1 in tumorigenesis. Ann N Y Acad
Sci. 2012;1271:10–9.
85. Michan S, Li Y, Chou MMH, Parrella E, Ge HY, Long JM, et al. SIRT1 is
essential for normal cognitive function and synaptic plasticity. J Neurosci.
2010;30(29):9695–707.
86. Veltman JA, Brunner HG. Applications of next-generation sequencing de
novo mutations in human genetic disease. Nat Rev Genet. 2012;13(8):
565–75.
87. Niemi MEK, Martin HC, Rice DL, Gallon G, Gordon S, Kelemen M, et al.
Common genetic variants contribute to risk of rare severe
neurodevelopmental disorders. Nature. 2018;562(7726):268.
88. Lasalle JM. Autism genes keep turning up chromatin. OA Autism. 2013;
1(2):14.
89. Cotney J, Muhle RA, Sanders SJ, Liu L, Willsey AJ, Niu W, et al. The autism-
associated chromatin modifier CHD8 regulates other autism risk genes
during human neurodevelopment. Nat Commun. 2015;6:6404.
90. Chauvette S, Soltani S, Seigneur J, Timofeev I. In vivo models of cortical
acquired epilepsy. J Neurosci Meth. 2016;260:185–201.
91. Sloviter RS. Decreased hippocampal inhibition and a selective loss of
interneurons in experimental epilepsy. Science. 1987;235(4784):73–6.
92. Swann JW, Al-Noori S, Jiang MH, Lee CL. Spine loss and other dendritic
abnormalities in epilepsy. Hippocampus. 2000;10(5):617–25.
93. Gagnon D, Petryszyn S, Sanchez MG, Bories C, Beaulieu JM, De Koninck Y,
et al. Striatal neurons expressing D-1 and D-2 receptors are morphologically
distinct and differently affected by dopamine denervation in mice. Sci Rep.
2017;7:41432.
94. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ, et al. D1
and D2 dopamine receptor regulated gene-expression of striatonigral and
striatopallidal neurons. Science. 1990;250(4986):1429–32.
95. Perreault ML, Hasbi A, O’Dowd BF, George SR. The dopamine D1-D2
receptor heteromer in striatal medium spiny neurons: evidence for a third
distinct neuronal pathway in basal ganglia. Front Neuroanat. 2011;5:31.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Chow et al. Genome Medicine           (2019) 11:65 Page 14 of 14
